Transmedics Group Inc’s filing revealed that its Director EDWARD BASILE acquired Company’s shares for reported $0.63 million on May 27 ’25. In the deal valued at $126.45 per share,5,000 shares were bought.
Then, Weill David sold 732 shares, generating $90,680 in total proceeds. Upon selling the shares at $123.88, the Director now owns 12,134 shares.
Before that, DAVID WEILL bought 732 shares. Transmedics Group Inc shares valued at $90,683 were divested by the Director at a price of $123.88 per share.
JP Morgan downgraded its Transmedics Group Inc [TMDX] rating to a Neutral from a an Overweight in a research note published on December 17, 2024; the price target was decreased to $75 from $116. A number of analysts have revised their coverage, including Needham’s analysts, who decreased its forecast for the stock in late November from “a Buy” to “a Hold”. Oppenheimer also remained covering TMDX and reiterated its “an Outperform” recommendation on October 29, 2024. Needham maintained its rating on October 29, 2024. It rated TMDX as “a Buy”.
Price Performance Review of TMDX
On Tuesday, Transmedics Group Inc [NASDAQ:TMDX] saw its stock jump 3.44% to $128.53. Over the last five days, the stock has gained 5.27%. Transmedics Group Inc shares have risen nearly 106.14% since the year began. Nevertheless, the stocks have fallen -6.16% over the past one year. While a 52-week high of $177.37 was reached on 05/27/25, a 52-week low of $55.00 was recorded on 01/21/25. SMA at 50 days reached $90.23, while 200 days put it at $98.61.
Levels Of Support And Resistance For TMDX Stock
The 24-hour chart illustrates a support level at 126.38, which if violated will result in even more drops to 124.24. On the upside, there is a resistance level at 130.54. A further resistance level may holdings at 132.56. The Relative Strength Index (RSI) on the 14-day chart is 80.14, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 7.42, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 4.96%. Stochastics %K at 96.88% indicates the stock is a selling.
The most recent change occurred on September 24, 2024 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $200 price target.
